Cytokinetics
Price
Price
Frequently asked questions
What is Cytokinetics's market capitalization?
What is the Earnings Per Share (EPS) for Cytokinetics?
What are the analyst ratings and target price for Cytokinetics's stock?
What is Cytokinetics's revenue over the trailing twelve months?
What is the EBITDA for Cytokinetics?
What is the free cash flow of Cytokinetics?
What is the 5-year beta of Cytokinetics's stock?
How many employees does Cytokinetics have, and what sector and industry does it belong to?
What is the free float of Cytokinetics's shares?
Financials
Market Cap
$5.63B5Y beta
0.79EPS (TTM)
-$5.388Free Float
116.44MRevenue (TTM)
$3.22MEBITDA (TTM)
-$511.14MFree Cashflow (TTM)
-$407.05MPricing
Analyst Ratings
The price target is $83.88 and the stock is covered by 19 analysts.
Buy
15
Hold
4
Sell
0
Information
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
423
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker